• Reference Citation Analysis
  • Login
    Academic Contribution Register
    Editorial Board Register
    Business Register
  • v
  • v
  • Find an Article
Find an Article PDF (4678539)   Today's Articles (3038)
For: Birnbaum T, Stadler EA, von Baumgarten L, Straube A. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol 2012;109:285-91. [DOI: 10.1007/s11060-012-0891-7] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/02/2012] [Accepted: 04/23/2012] [Indexed: 10/28/2022]
Number Cited by Other Article(s)
1
Tringale KR, Scordo M, Yahalom J, White C, Zhang Z, Vachha B, Cederquist G, Schaff L, DeAngelis L, Grommes C, Imber BS. Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro Oncol 2024;26:2061-2073. [PMID: 38915246 PMCID: PMC11534311 DOI: 10.1093/neuonc/noae115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 02/18/2024] [Indexed: 06/26/2024]  Open
2
Suleman A, Wine R, Carrier M, Hicks LK. The risk of venous thromboembolism in primary central nervous system lymphoma: a systematic review and meta-analysis. Res Pract Thromb Haemost 2024;8:102507. [PMID: 39328375 PMCID: PMC11424797 DOI: 10.1016/j.rpth.2024.102507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 04/17/2024] [Revised: 06/20/2024] [Accepted: 07/02/2024] [Indexed: 09/28/2024]  Open
3
Wang Y, Cui C, Raza HK, Chen H, Wang X, Zhang W, Meng W, Li K, Mao Z, Sun X, Zhang S. Pathological and imaging features, treatment, and prognosis of primary intraventricular lymphoma: A review of cases from a single center. Heliyon 2024;10:e27942. [PMID: 38496845 PMCID: PMC10944254 DOI: 10.1016/j.heliyon.2024.e27942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 12/22/2023] [Revised: 03/07/2024] [Accepted: 03/08/2024] [Indexed: 03/19/2024]  Open
4
Zhang Y, Liu Z, Gao C, Bian H, Ma Y, Jing F, Zhao X. Role of Rituximab in Treatment of Patients With Primary Central Nervous System Lymphoma (PCNSL): A Systematic Review and Meta-Analysis. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2023;23:733-741. [PMID: 37453867 DOI: 10.1016/j.clml.2023.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Academic Contribution Register] [Received: 03/10/2023] [Revised: 06/10/2023] [Accepted: 06/23/2023] [Indexed: 07/18/2023]
5
Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, Roth P, Rudà R, Schlegel U, Soffietti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol 2023;25:37-53. [PMID: 35953526 PMCID: PMC9825335 DOI: 10.1093/neuonc/noac196] [Citation(s) in RCA: 60] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/14/2022] [Indexed: 01/12/2023]  Open
6
Thumrongsiri N, Dana P, Bawab R, Tanyapanyachon P, Treetidnipa C, Saengkrit N, Sathornsumetee S. Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma. Biomed Pharmacother 2022;150:112979. [PMID: 35461090 DOI: 10.1016/j.biopha.2022.112979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 02/15/2022] [Revised: 04/08/2022] [Accepted: 04/14/2022] [Indexed: 11/02/2022]  Open
7
Lee JY, Paik JH, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. Blood Res 2021;56:285-292. [PMID: 34801986 PMCID: PMC8721461 DOI: 10.5045/br.2021.2021073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 04/12/2021] [Revised: 08/27/2021] [Accepted: 10/18/2021] [Indexed: 11/17/2022]  Open
8
Nakajima K, Mizobuchi Y, Fujihara T, Azumi M, Takagi Y. Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma. THE JOURNAL OF MEDICAL INVESTIGATION 2021;68:286-291. [PMID: 34759146 DOI: 10.2152/jmi.68.286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/14/2022]
9
Alcantara M, Fuentealba J, Soussain C. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. Cancers (Basel) 2021;13:cancers13205061. [PMID: 34680209 PMCID: PMC8534133 DOI: 10.3390/cancers13205061] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 08/04/2021] [Revised: 09/29/2021] [Accepted: 10/05/2021] [Indexed: 12/11/2022]  Open
10
Kaji FA, Martinez-Calle N, Bishton MJ, Figueroa R, Adlington J, O'Donoghue M, Smith S, Byrne P, Paine S, Sovani V, Auer D, James E, Bessell EM, Grainge MJ, Fox CP. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. Br J Haematol 2021;195:561-570. [PMID: 34368948 DOI: 10.1111/bjh.17747] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 05/04/2021] [Accepted: 07/19/2021] [Indexed: 01/01/2023]
11
The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma. Cancers (Basel) 2021;13:cancers13081920. [PMID: 33923396 PMCID: PMC8074001 DOI: 10.3390/cancers13081920] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/24/2021] [Revised: 04/06/2021] [Accepted: 04/13/2021] [Indexed: 01/17/2023]  Open
12
Liu Y, Yao Q, Zhang F. Diagnosis, prognosis and treatment of primary central nervous system lymphoma in the elderly population (Review). Int J Oncol 2021;58:371-387. [PMID: 33650642 PMCID: PMC7864151 DOI: 10.3892/ijo.2021.5180] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 10/20/2020] [Accepted: 01/18/2021] [Indexed: 12/14/2022]  Open
13
Sasaki N, Kobayashi K, Saito K, Shimizu S, Suzuki K, Lee J, Yamagishi Y, Shibahara J, Takayama N, Shiokawa Y, Nagane M. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Jpn J Clin Oncol 2020;50:999-1008. [PMID: 32469065 DOI: 10.1093/jjco/hyaa073] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 02/03/2020] [Accepted: 05/04/2020] [Indexed: 11/12/2022]  Open
14
Holdhoff M, Wagner-Johnston N, Roschewski M. Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. Onco Targets Ther 2020;13:8323-8335. [PMID: 32903865 PMCID: PMC7445492 DOI: 10.2147/ott.s192379] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/05/2020] [Accepted: 06/30/2020] [Indexed: 12/16/2022]  Open
15
Zheng X, Yang S, Chen F, Wu S, Li W. The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:1213. [PMID: 32903796 PMCID: PMC7438862 DOI: 10.3389/fonc.2020.01213] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 04/28/2020] [Accepted: 06/15/2020] [Indexed: 02/03/2023]  Open
16
The Role of Rituximab in Primary Central Nervous System Lymphoma. Curr Oncol Rep 2020;22:78. [PMID: 32602069 PMCID: PMC7324418 DOI: 10.1007/s11912-020-00941-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/04/2022]
17
Kawazoe M, Kaneko K, Nanki T. Methotrexate-associated lymphoproliferative disorders in the central nervous system and stomach: A case report. Medicine (Baltimore) 2020;99:e19850. [PMID: 32282749 PMCID: PMC7220667 DOI: 10.1097/md.0000000000019850] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Academic Contribution Register] [Indexed: 11/26/2022]  Open
18
Houillier C, Soussain C, Ghesquières H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agapé P, Moluçon-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology 2020;94:e1027-e1039. [PMID: 31907289 DOI: 10.1212/wnl.0000000000008900] [Citation(s) in RCA: 149] [Impact Index Per Article: 29.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 04/12/2019] [Accepted: 09/05/2019] [Indexed: 11/15/2022]  Open
19
Singh PK, Pan E. Review of rituximab in primary CNS lymphoma. J Neurol Sci 2019;410:116649. [PMID: 31901591 DOI: 10.1016/j.jns.2019.116649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 06/24/2019] [Revised: 12/23/2019] [Accepted: 12/24/2019] [Indexed: 10/25/2022]
20
Seidel S, Schlegel U. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. Expert Rev Anticancer Ther 2019;19:909-915. [DOI: 10.1080/14737140.2019.1677157] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 10/25/2022]
21
Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus G, Issa S, Schorb E, Zucca E, Hemkens LG, Schandelmaier S, Kasenda B. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol 2019;37:548-557. [PMID: 31418878 DOI: 10.1002/hon.2666] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 07/15/2019] [Revised: 08/09/2019] [Accepted: 08/10/2019] [Indexed: 01/17/2023]
22
Seidel S, Korfel A, Kowalski T, Margold M, Ismail F, Schroers R, Baraniskin A, Pels H, Martus P, Schlegel U. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis. Neurol Res Pract 2019;1:17. [PMID: 33324883 PMCID: PMC7650117 DOI: 10.1186/s42466-019-0024-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/29/2019] [Accepted: 04/26/2019] [Indexed: 11/10/2022]  Open
23
Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book 2019;39:454-466. [PMID: 31099614 DOI: 10.1200/edbk_242547] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/20/2022]
24
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2019;20:216-228. [PMID: 30630772 DOI: 10.1016/s1470-2045(18)30747-2] [Citation(s) in RCA: 147] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 07/28/2018] [Revised: 09/27/2018] [Accepted: 10/01/2018] [Indexed: 10/27/2022]
25
Da Broi M, Jahr G, Beiske K, Holte H, Meling TR. Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL. Blood Cells Mol Dis 2018;73:25-32. [PMID: 30217760 DOI: 10.1016/j.bcmd.2018.08.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 08/23/2018] [Accepted: 08/29/2018] [Indexed: 12/26/2022]
26
Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X, Li L, Wang X, Zhang X, Li Z, Yu H, Chang Y, Nan F, Yan J, Tian L, Wang X, Zhang M. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. J Neurooncol 2018;140:427-434. [PMID: 30109672 PMCID: PMC6244785 DOI: 10.1007/s11060-018-2970-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/25/2018] [Accepted: 08/05/2018] [Indexed: 12/30/2022]
27
Farhi J, Laribi K, Orvain C, Hamel JF, Mercier M, Sutra Del Galy A, Clavert A, Rousselet MC, Tanguy-Schmidt A, Hunault-Berger M, Moles-Moreau MP. Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma. Ann Hematol 2018;97:2391-2401. [PMID: 30091022 DOI: 10.1007/s00277-018-3468-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 05/27/2018] [Accepted: 07/31/2018] [Indexed: 12/16/2022]
28
Sinicrope K, Batchelor T. Primary Central Nervous System Lymphoma. Neurol Clin 2018;36:517-532. [DOI: 10.1016/j.ncl.2018.04.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/28/2022]
29
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leuk Lymphoma 2018;60:6-18. [DOI: 10.1080/10428194.2018.1466296] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 12/18/2022]
30
Sun X, Liu J, Wang Y, Bai X, Chen Y, Qian J, Zhu H, Liu F, Qiu X, Sun S, Ji N, Liu Y. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget 2018;8:49156-49164. [PMID: 28467782 PMCID: PMC5564757 DOI: 10.18632/oncotarget.17101] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 12/21/2016] [Accepted: 04/02/2017] [Indexed: 12/26/2022]  Open
31
Citterio G, Calimeri T, Ferreri AJM. Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. Expert Rev Neurother 2018;18:379-393. [PMID: 29633883 DOI: 10.1080/14737175.2018.1462700] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 12/11/2022]
32
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 2018;93:57-68. [PMID: 29477102 DOI: 10.1016/j.ejca.2018.01.073] [Citation(s) in RCA: 84] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 09/23/2017] [Revised: 12/24/2017] [Accepted: 01/09/2018] [Indexed: 12/17/2022]
33
Miyakita Y, Ohno M, Takahashi M, Muragaki Y, Katai H, Narita Y. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL). Jpn J Clin Oncol 2017;47:919-924. [PMID: 28981729 DOI: 10.1093/jjco/hyx095] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 11/06/2016] [Accepted: 06/19/2017] [Indexed: 11/14/2022]  Open
34
Song Y, Wen Y, Xue W, Zhang Y, Zhang M. Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. Int J Hematol 2017;106:612-621. [PMID: 28900847 DOI: 10.1007/s12185-017-2316-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 04/04/2017] [Revised: 08/08/2017] [Accepted: 08/08/2017] [Indexed: 11/29/2022]
35
Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y, Zhou S, Wang X, Xu J, Tao R. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther 2017;10:2595-2600. [PMID: 28553124 PMCID: PMC5440074 DOI: 10.2147/ott.s134684] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/23/2022]  Open
36
Citterio G, Reni M, Gatta G, Ferreri AJM. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2017;113:97-110. [DOI: 10.1016/j.critrevonc.2017.03.019] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 11/07/2016] [Revised: 02/24/2017] [Accepted: 03/15/2017] [Indexed: 12/26/2022]  Open
37
Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol 2017;133:315-320. [DOI: 10.1007/s11060-017-2435-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 11/17/2016] [Accepted: 04/15/2017] [Indexed: 10/19/2022]
38
Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundström C, Amini RM, Hagberg H. Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. Acta Oncol 2017;56:599-607. [PMID: 28084866 DOI: 10.1080/0284186x.2016.1270465] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 12/22/2022]
39
Primary central nervous system lymphoma: essential points in diagnosis and management. Med Oncol 2017;34:61. [PMID: 28315229 DOI: 10.1007/s12032-017-0920-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 03/02/2017] [Accepted: 03/14/2017] [Indexed: 12/19/2022]
40
Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol 2017;177:72-79. [DOI: 10.1111/bjh.14522] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 08/10/2016] [Accepted: 10/10/2016] [Indexed: 11/29/2022]
41
Kuitunen H, Tokola S, Siniluoto T, Isokangas M, Sonkajärvi E, Alahuhta S, Turpeenniemi-Hujanen T, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL). J Neurooncol 2016;131:293-300. [DOI: 10.1007/s11060-016-2293-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 05/05/2016] [Accepted: 10/09/2016] [Indexed: 11/29/2022]
42
Cordone I, Masi S, Carosi M, Vidiri A, Marchesi F, Marino M, Telera S, Pasquale A, Mengarelli A, Conti L, Pescarmona E, Pace A, Carapella CM. Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2016;35:128. [PMID: 27567676 PMCID: PMC5002320 DOI: 10.1186/s13046-016-0404-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Academic Contribution Register] [Received: 05/31/2016] [Accepted: 08/09/2016] [Indexed: 01/06/2023]
43
Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016;3:e217-27. [PMID: 27132696 DOI: 10.1016/s2352-3026(16)00036-3] [Citation(s) in RCA: 403] [Impact Index Per Article: 44.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 02/11/2016] [Revised: 02/24/2016] [Accepted: 03/03/2016] [Indexed: 12/16/2022]
44
Ly KI, Crew LL, Graham CA, Mrugala MM. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett 2016;11:3471-3476. [PMID: 27123138 DOI: 10.3892/ol.2016.4393] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 02/24/2015] [Accepted: 02/02/2016] [Indexed: 11/05/2022]  Open
45
The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 2016;127:1642-9. [PMID: 26834241 DOI: 10.1182/blood-2015-10-636340] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 10/23/2015] [Accepted: 01/27/2016] [Indexed: 12/17/2022]  Open
46
Cho MS, Kim JY, Jung SY, Ahn SY, Song GY, Yang DH. Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma. Blood Res 2016;51:285-287. [PMID: 28090494 PMCID: PMC5234245 DOI: 10.5045/br.2016.51.4.285] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 02/18/2016] [Revised: 03/10/2016] [Accepted: 03/16/2016] [Indexed: 11/17/2022]  Open
47
Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol 2015;90:1149-54. [PMID: 26414492 DOI: 10.1002/ajh.24204] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Received: 07/22/2015] [Revised: 09/02/2015] [Accepted: 09/23/2015] [Indexed: 11/11/2022]
48
Recent developments and controversies in primary central nervous system lymphoma. Curr Opin Oncol 2015;27:496-501. [DOI: 10.1097/cco.0000000000000233] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/26/2022]
49
Citterio G, Reni M, Ferreri AJM. Present and future treatment options for primary CNS lymphoma. Expert Opin Pharmacother 2015;16:2569-79. [DOI: 10.1517/14656566.2015.1088828] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 12/18/2022]
50
Kelly CM, O'Dowd S, Drake C, McCarthy L, Bermingham N, Fanning N, O'Sullivan SS, O'Reilly S. Clinical Reasoning: Vanishing tumor: A 7-year puzzle solved. Neurology 2015;85:e69-73. [PMID: 26324866 DOI: 10.1212/wnl.0000000000001881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Academic Contribution Register] [Indexed: 11/15/2022]  Open
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel